News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Stroke Association Release: MATCH Trial Results May Simplify Hundreds Of Thousands Of Patient Lives



10/19/2005 5:08:50 PM

ENGLEWOOD, Colo., June 24 /PRNewswire/ -- Hundreds of thousands of patients currently take clopidigrel (Plavix(R)) plus aspirin to reduce their recurrent stroke risk. Today at the 5th International Stroke Society World Congress in Vancouver, B.C., researchers reported that the addition of aspirin to clopidigrel does not significantly reduce the risk of recurrent stroke after a stroke or transient ischemic attack (TIA) also known as a mini stroke. For many patients this means one less drug to take in their daily regimen.

The Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attacks or Ischemic Stroke (MATCH) trial was conducted with 7,599 patients in 28 countries and is the largest study to date with such a high-risk population.

The study also showed that the addition of aspirin to clopidigrel significantly increased the risk of hemorrhagic stroke.

"Stroke survivors run a 5 percent to 15 percent risk of a recurrent stroke in the first year. Many times these strokes are more debilitating or deadly. Any research that clarifies the best way to reduce recurrent stroke risk is very important for stroke survivors to understand, said James Baranski, CEO of National Stroke Association.

Dr. Lawrence Brass, Neurologist at Yale University says, "This study also reminds doctors that we need to consider all prevention methods to reduce recurrent stroke risk, and not just prescribe anti-platelet therapy."

While MATCH looked at clopidigrel plus aspirin, other studies of antiplatelet combination therapy have shown increased stroke risk reduction. The European Stroke Prevention Study2 showed that the combination of aspirin with dipyridamole (Aggrenox(R)) is more effective than aspirin alone.

National Stroke Association wants patients to ask their doctors about the latest in stroke treatment and the best way to reduce their risk of recurrent stroke.

Based in Englewood, Colo., National Stroke Association is a leading, independent national nonprofit organization devoting 100 percent of its efforts and resources to stroke. For more information contact NSA at 1-800-STROKES (767-6537) or visit http://www.stroke.org/. For interviews with Jim Baranski or Dr. Larry Brass on this release please call Diane Mulligan-Fairfield.

National Stroke Association

CONTACT: Contact: Diane Mulligan-Fairfield, Vice President, NationalCommunications of National Stroke Association, +1-303-754-0920


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES